Q-omics provides the consensus-scored ZBTB7B profile across patient tissues and cancer cell-line models. ZBTB7B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZBTB7B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, ZBTB7B RNA expression shows 20,247 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where ZBTB7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB7B survival associations across molecular data types. ZBTB7B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB7B RNA expression–survival associations across cancer types. High ZBTB7B expression shows unfavorable associations in UVM, LGG and KIRP, but favorable associations in KIRC, MESO and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZBTB7B RNA expression.
This table summarizes ZBTB7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZBTB7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB7B shows lower tumor expression in COAD and KICH and higher tumor expression in KIRC, LIHC, LUAD and UCEC. The KIRC box plot shows higher ZBTB7B RNA expression in tumor versus normal tissue (log2 FC = +0.722, t-test p < 0.001).
This table shows molecular features associated with ZBTB7B in patient tissues and cancer cell lines. In patient samples, ZBTB7B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZBTB7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
